The following posts regarding IOVA appeared on another site today by the poster JGalt24. Iovance did speak at a private management fireside chat at Stifel's 2024 Virtual Cell Therapy Forum today, July 9th. Here's the posts:
(2:52 pm) "The timing of the move up today coincided with the move in Xbi, but Iova also presented at the Stifel Cell Therapy Conference at 11:30am and made an interesting comment a few minutes in when asked about timing of guidance moving forward. Bellemin-CFO, and Gastman-EVP Medical Affairs presented btw. Bellemin said they guided to how many pts were enrolled during Q1 call. During Q2 call, looking towards Q3, they will “go one step further”. I assume that means they will guide to:
a. #of pts actually treated or expected to be treated vs enrolled, or
b. actual revenues
I would guess (a) for this Q but would love to be surprised, he sounded very positive about it. Either way, this should help in removing some of the concern around lack of visibility and/or help analysts start to feel more confident in modeling future revenues."
(3:15 pm answering a question): "Not a Stifel client. Factset pulls in news from most of the sell side firms. I have access to several firms’ research, but Stifel isn’t one of them. Luckily was still able to get access through factset. Sometimes that works, sometimes not if it isn’t publicly available through companies’ website."
(3:32 pm): "A couple of other notes:
-On reimbursement: “not an issue”; no coverage for an individual pt has yet been denied; 200M lives covered in the US and growing as per plan
-Patient attrition in line with early CAR-T #’s and expected to improve at a similar pace; ATC’s getting better at selecting pts
-confirmed about 50 atc’s and 70 by y-e; ALL have enrolled pts at this point; some of the newer ones have surpassed those that were involved in trials
-Capacity: haven’t hit constraints yet at atc’s, some are talking about expanding or building around demand for this treatment
-commented that some physicians are creating their careers around cell therapy, reflecting excitement in the industry
All sounds very positive, just need to be patient for another couple of quarters to see consistent revenues"
I don't know this poster, but all stacks up to what we've heard before. Several very good takeaways. Enjoy.
Badgerkid
